SHARE PRICE > View All Stock Detailed Share Information Latest News Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference > View All News All News Upcoming Events More events are coming soon. > View All Events All Events Latest Presentation August 25, 2026 Corporate Presentation – Half-Year 2026 Financials May 12, 2026 Corporate Presentation – Q1 financials, May 2026 March 12, 2026 Corporate Presentation – Full Year 2025 Financials > View All Presentations All Presentations Latest Financial Documents August 25, 2026 H1 2026 Financial Statements May 12, 2026 Q1 Financial Statement 2026 April 16, 2026 Molecular Partners statement regarding Passive Foreign Investment Company status > View All Reports All Annual Report Seth Lewis,EVP Corporate FinanceContact SethSTAY INFORMEDSubscribe to email alerts of your choosingSUBSCRIBEInstitutional investors: REQUEST 1-1 / CALLpowered by schedulR
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
